



**CROHN'S
& COLITIS
FOUNDATION**

The premier product development conference in IBD

IBD INNOVATE™

Novel Therapies, Diagnostics, and Devices for IBD

**The premier IBD product development
conference for therapeutics, diagnostics,
devices, and digital health.**

April 9–10, 2025

West End Labs

125 West End Avenue

New York, NY 10023



Welcome to IBD Innovate 2025!

The Crohn's & Colitis Foundation welcomes you to the premier IBD product development event highlighting novel therapeutics, diagnostics, devices, and digital health technologies for inflammatory bowel disease (IBD). Now in its seventh year, IBD Innovate stands as the only conference that unites the entire IBD product development ecosystem to advance next-generation solutions for IBD patients.

Our distinguished keynote speakers will address critical gaps in IBD therapeutic strategies and explore the path towards disease prevention. Our presenters will delve into therapeutic approaches and clinical endpoints for fibrostenotic and fistulizing disease, novel technologies, and the potential of digital twins in healthcare. Don't miss our exciting IBD Innovate Shark Tank session, where innovative ideas take center stage. Join us to learn, share, and be at the forefront of IBD innovation.

Foundation Organizing Committee

Scientific Agenda



Alan Moss, MD
Chief Scientific Officer



Andrés Hurtado-Lorenzo, PhD
*Senior Vice President,
Translational Research & IBD Ventures*



Joni Hamlet
*Associate Director,
Mission Events &
Meetings*



Russell Wyborski, PhD
*Director,
IBD Ventures Investments*



Nicole Schwerbrock, PhD
*Associate Director,
IBD Ventures Investments*

Registration and Event Information



<https://cvent.me/gD9NKG>

Social Media

Join the conversation on social media using hashtag **#IBDInnovate25**.

Contact

Program-related inquiries:

Nicole Schwerbrock
Innovate25@crohnscolitisfoundation.org

Sponsorship-related inquiries:

Andy Robertson
arobertson@crohnscolitisfoundation.org
or 832-720-8191

AGENDA

Day One: April 9, 2025

What's next for IBD patients? Emerging products on the horizon

Time	Title	Speaker	Affiliation
8:00–9:00 a.m.	Breakfast/Registration		
9:00–9:15 a.m.	Welcome: IBD Ventures & IBD Innovate	Andrés Hurtado-Lorenzo, PhD <i>Senior Vice President, Translational Research & IBD Ventures</i>	Crohn's & Colitis Foundation
KEYNOTE: Gaps in IBD therapeutic strategy Moderator: Andrés Hurtado-Lorenzo, PhD			
9:15–10:00 a.m.	Gaps in IBD therapeutic strategy	Peter Higgins, MD, PhD, MSc, AGAF <i>Timothy T. Nostrant Endowed Chair of Gastroenterology</i>	University of Michigan
SESSION 1: Therapeutic approaches and clinical endpoints for fibrostenosis		Moderator: Andrés Hurtado-Lorenzo, PhD	
10:00–10:15 a.m.	Anti-fibrotic therapy for fibrostenosing CD: The end of the beginning?	Brian G. Feagan, MD <i>Professor of Medicine, Epidemiology and Biostatistics</i>	Western University— Ontario, Canada
10:15–10:30 a.m.	MBF-118. A PPAR γ partial agonist for the treatment of fibro-stenosing Crohn's disease	Richard Roberts, PhD CSO	Medibiofarma
10:30–10:45 a.m.	Fibro-inflammatory biomarkers in IBD: Protein fingerprints for serological assessment of mucosal damage and intestinal Fibrosis	Joachim Høg Mortensen, MSc, PhD <i>Scientific Director</i>	Nordic Bioscience
10:45–11:10 a.m.	Q&A with speakers		
11:10–11:30 a.m.	Break/Networking		
SESSION 2: Therapeutics and clinical endpoints for fistulizing disease		Moderator: Alan Moss, MD	
11:30–11:45 a.m.	Fistulizing perianal Crohn's disease	Stefan Holubar, MD, MS, FACS, FASCRS <i>Director of Research</i>	Cleveland Clinic
11:45 a.m.– 12:00 p.m.	MSC extracellular vesicles in IBD: A path to clinical translation and therapeutic innovation	Tim Moseley, PhD CSO	Direct Biologics
12:00–12:15 p.m.	Self-assembling peptide: A new approach to mucosal healing in IBD	Vincent Mortureux <i>Head of Research and Development</i>	3-D Matrix
12:15–12:30 p.m.	Novel source of adult multipotent stem cells to heal Crohn's perianal fistulas	Jeff Moore, PhD <i>CEO and Founder</i>	Curileum Discovery
12:30–12:45 p.m.	Q&A with speakers		
12:45–2:00 p.m.	Lunch/Networking		
2:00–2:30 p.m.	Navigating the unseen: My journey with Crohn's disease	Saxl Rose	Patient Stakeholder

AGENDA

Day One: April 9, 2025

Time	Title	Speaker	Affiliation
KEYNOTE: Digital twins to advance precision medicine in IBD Moderator: Russell Wyborski, PhD			
2:30–3:15 p.m.	Digital twins to advance precision medicine in IBD	Marija Radic, PhD <i>Head of Digital Health</i>	Fraunhofer Center for International Management and Knowledge Economics, Germany
SESSION 3: Precision medicine in IBD		Moderator: Russell Wyborski, PhD	
3:15–3:30 p.m.	From data to diagnosis: Using digital histopathology to drive precision medicine in IBD	Sana Syed, MD, MSCR, MSDS <i>Associate Professor</i>	Duke University School of Medicine — Department of Pediatrics
3:30–3:45 p.m.	Precision medicine at the intersection of AI and IBD	Cristina Larkin <i>CEO</i>	Mobius Care
3:45–4:00 p.m.	Opportunities for liquid biopsy in IBD via microbial cell-free DNA: from diagnosis to monitoring	Shiv Kale, PhD <i>Director, Computational Biomarker Discovery</i>	Karius
4:00–4:20 p.m.	Q&A with speakers		
4:20–6:00 p.m.	Poster Session/Networking		

AGENDA

Day Two: April 10, 2025

8:00–8:45 a.m.	Breakfast/Registration/Welcome	Russell Wyborski, PhD <i>Director, IBD Ventures Investments</i>	Crohn's & Colitis Foundation
KEYNOTE: The road to inflammatory bowel disease prevention Moderator: Russell Wyborski, PhD			
8:45–9:30 a.m.	The road to inflammatory bowel disease prevention	Jean-Frédéric Colombel, MD	Professor of Gastroenterology and Internal Medicine, Icahn School of Medicine at Mount Sinai
SESSION 4: Novel technologies: Innovation in IBD therapeutics		Moderator: Nicole Schwerbrock, PhD	
9:30–9:45 a.m.	Summiting Mt. Cure: Forging a new path in Crohn's disease treatment	Nick Conley, PhD <i>Chief Technology Officer</i>	Locus Biosciences
9:45–10:00 a.m.	Highly penetrating nanodisc for targeted remodeling of Crohn's disease fibrosis	Ahme Elzoghby, MSc, PhD <i>Instructor in Medicine</i>	Harvard Medical School
10:00–10:15 a.m.	EASE Platform: Developing a 'Living Pharmacy' to deliver Anti-TNF therapy with an implantable bioelectronic device	Alexander Revzin, PhD <i>Professor, Department of Physiology and Biomedical Engineering</i>	Mayo Clinic
10:15–10:30 a.m.	Q&A with Funding Panel		
10:30–11:00 a.m.	Break/Networking		

AGENDA

Day Two: April 10, 2025

11:00 a.m.–12:20 p.m.		IBD Innovate Shark Tank	Moderator: Scott Plevy, MD Judges: Peter Higgins, MD, PhD <i>CCF NSAC Chair</i> ; Julie Di Paolo, PhD <i>Johnson & Johnson</i> ; Saxl Rose <i>Patient Stakeholder</i> ; Nadim Shohdy, PhD <i>Deerfield, 3DC</i> ; Colby Kash, DC <i>Camelot BioCapital</i>	
11:05–11:20 a.m.	(S)-IBD3540: A first-in-class oral GCP11 inhibitor for IBD inflammation and pain	Diane Peters, DVM, PhD <i>Assistant Professor and Senior Pharmacologist</i>	Johns Hopkins Drug Discovery	
11:20–11:35 a.m.	IMIDEology-data-driven precision care for immune-mediated inflammatory diseases such as Crohn’s and colitis	Jin Lee, PhD <i>Co-Founder and CEO</i>	IMIDEology Clinic	
11:35–11:50 a.m.	Highly accurate AI-discovered and validated tumor necrosis factor inhibitor (TNFi) treatment response predictor for patients with inflammatory bowel disease	Claudio Faria, PharmD, MPH <i>Co-Founder and CEO</i>	Ignite Biomedical	
11:50–12:05 p.m.	Home- and office-based remote rapid monitoring platform for superior IBD disease management	Yuval Almougy <i>CEO</i>	Harp Diagnostics	
12:05–12:20 p.m.	MH002—the most advanced live biotherapeutic for inflammatory bowel diseases—combines efficacy and novel mode-of-action with excellent safety profile in Phase 2a studies in ulcerative colitis and pouchitis	Sam Possemiers, PhD <i>CEO</i>	MRM Health	
12:20–1:45 p.m.	Lunch/Networking			
SESSION 5: Nutraceuticals & microbiome therapeutics		Moderator: Nicole Schwerbrock, PhD		
1:45–2:00 p.m.	CurQD: Truly breaking the therapeutic ceiling	Nir Salomon <i>Co-founder</i>	Evinature	
2:00–2:15 p.m.	Early Phase 1 clinical insights: Get a first look at the Phase 1 clinical trial results of EXL01 in the treatment of Crohn’s disease	Benjamin Hadida, MSc, MM <i>CEO and Co-founder</i>	Exeliom Biosciences	
2:15–2:30 p.m.	Mining small molecules from gut microbes to treat IBD	Kareem Barghouti, MBA <i>CEO and Co-founder</i>	Pragma Bio	
SESSION 6: GPCRs: Druggable targets with genetic linkage		Moderator: Andrés Hurtado-Lorenzo, PhD		
2:30–2:45 p.m.	Bridging the divide between genetics and drug discovery: GPR65 case study	Daniel Graham, PhD <i>Senior Director of Functional Genomics</i>	Broad Institute of MIT and Harvard University via Zoom	
2:45–3:00 p.m.	Beyond cytokines in colitis: Epithelial damage prevention through GPR35 inhibition to improve patient outcomes	Christopher Luckhurst, PhD <i>Head of Chemistry</i>	ThirtyFiveBio	
3:00–3:15 p.m.	Q&A with speakers			
3:15–3:30 p.m.	IBD Innovate Shark Tank winner announcement			
3:30–4:00 p.m.	Concluding remarks and meeting wrap-up			

POSTERS

April 9, 2025

Number	Organization	Category	Presenter	Poster Title
1	Thetis	Therapeutic	Gary Mathias, MBA <i>Co-Founder and Chief Executive Officer</i>	PK/PD, safety and efficacy of oral Resolvin E1-based therapy in IBD: Translating RvE1 activation of BLT1 in experimental models to healthy volunteers
2	Allonix	Therapeutic	Eric Ortlund, PhD Kohn Calvert, PhD <i>Co-Founders</i>	Modulation of LRH-1 Ameliorates DSS-Induced Colitis
3	Evotec	Platform	Manjula Donepudi, PhD <i>VP, Business Development</i>	Modeling inflammatory bowel disease in mice with “humanized” immune system
4	Medipace	Device	Victor Pikov <i>CEO</i>	Vagal nerve controls several anti-inflammatory signaling pathways in IBD
5	Endo Tag	Therapeutic	Jørgen Olsen, MD, DMSc <i>CEO and Professor</i>	Topical insulin: A first-in-class IBD therapy with strong safety and commercial appeal
6	Intact Therapeutics	Delivery system	Karolin Jarr, MD <i>Medical Director</i>	The future of topical drug delivery to the distal colon: Potential of thermal hydrogel technology
7	Fzata	Therapeutic	Elizabeth Smith, PhD, MBA <i>Chief Business Officer</i>	Novel oral anti-TNF α for IBD
8	ImYoo	Platform	Tatyana Dobрева, PhD <i>CEO and Co-Founder</i>	Molecular insights from decentralized longitudinal profiling of flares in inflammatory bowel disease patients
9	Multiverse Pharma	Therapeutic	David Poon, PhD <i>Strategic Advisors</i>	Enhancing IBD treatment: Superior multispecific targeting of IL-12/IL-23 beyond Ustekinumab

POSTERS

April 10, 2025

Number	Organization	Category	Presenter	Poster Title
10	PIPr	Therapeutic	Heather Madsen, PhD <i>Operating Partner/ Hatteras Venture Partners</i>	PIPR-178, an enterically-restricted oral Bft inhibitor, reduces inflammation and promotes mucosal healing in a mouse IBD model
11	Demeetra	Therapeutic	Jack Crawford <i>CEO</i>	Cannabinoid medicinal chemistry has vast impact on pharmacology in mouse and rat models of inflammatory bowel disease
12	Microbiotica	Microbiome	Adam Wilkinson, PhD <i>VP, Pre-Clinical Development</i>	Mechanistic understanding of MB310: a consortium of gut commensal bacteria for the treatment of Ulcerative colitis
13	Altis	Platform	Jarret Bliton, PhD <i>Scientific Specialist</i>	A self-renewing, human-relevant in vitro inflammatory bowel disease model for phenotypic screening
14	Semiflex Dome System	Device	Sława Madelska <i>Co-founder and Patient Advocate</i>	Semiflex: A novel, patient-oriented solution for vacuum therapy of perianal fistulas

This conference is supported, in part, by:

Contributor Sponsors:



Our vision is to transform preclinical therapeutic development with best-in-class human cell-based model systems of the intestine. Our RepliGut® Systems are a series of intestinal epithelium models derived from regional specific adult stem cells for improving functional and mechanistic insights of new and emerging IBD therapeutics.



PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions. PhaseV platform has reduced trial costs by up to 25%, decreased enrollment size and trial duration by up to 40%, and increased the probability of success by up to 30%.

Host Sponsor:

west end labs

A high-performance research building designed specifically for those leading discovery, pushing innovation, and creating a brighter tomorrow—all within easy reach of New York's greater life science ecosystem. 125 West End Avenue, New York, NY 10023

CROHN'S & COLITIS FOUNDATION

733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423